We have been keeping a close eye on the development of congenital heart disease (CHD) medical technology. In 2005, we sponsored Children's Heart Foundation to introduce advanced equipment to the Cardiac Catheterization Laboratory. In 2018, we officially became the first enterprise in Hong Kong to support Percutaneous Pulmonary Valve Implantation (PPVI).
PPVI is a minimally invasive cardiac surgery, providing effective treatments for CHD patients when conventional thoracotomy is not an option for them due to their age, health condition or other reasons. PPVI can also largely reduce the surgery time and rehabilitation period, and the size of any scar, offering great help for both physical and mental recovery of the patients.
Our great attention and support to PPVI played a leading role! After more than a year, in 2019, the Pilot Scheme - PPVI was formally incorporated into the " regular assistance programmes " of the Hospital Authority to benefit more congenital heart disease patients in need.